Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab.
AMD
anti-VEGF
ocular drug delivery
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
17
07
2018
accepted:
20
11
2018
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
1
2
2019
Statut:
epublish
Résumé
To characterize a biodegradable microsphere-hydrogel drug delivery system (DDS) for controlled and extended release of ranibizumab. The degradable microsphere-hydrogel DDSs were fabricated by suspending ranibizumab-loaded or blank poly(lactic- All DDS formulations investigated were injectable through a 28-gauge needle at room temperature. The VPTT increased with increase of cross-linker concentration. The swelling ratios decreased as temperature increased and were not influenced by presence of microspheres. Rheology data confirmed that increase of cross-linker concentration and microsphere loading made DDS stiffer. Increase of degradable cross-linker concentration facilitated hydrogel in vitro degradation. Controlled release of ranibizumab were achieved for investigated DDS formulations for 6 months; and increased degradable cross-linker concentration produced faster and more complete release. The biodegradable DDSs are suitable for sustained release of ranibizumab. Considering ease of injection, degradability and release of ranibizumab, DDS with 3 mM cross-linker concentration and less than 20 mg/mL microsphere loadings is more favorable for future application. The investigated DDS is promising for controlled and extended release of anti-VEGF therapeutics to achieve better treatment regimen in ocular neovascularizations.
Identifiants
pubmed: 30701127
doi: 10.1167/tvst.8.1.12
pii: TVST-18-0999
pmc: PMC6350854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12Subventions
Organisme : NEI NIH HHS
ID : R15 EY025434
Pays : United States
Références
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
N Engl J Med. 2006 Oct 5;355(14):1432-44
pubmed: 17021319
Ophthalmology. 2007 Dec;114(12):2179-82
pubmed: 18054637
J Pharm Sci. 2010 Jul;99(7):3072-80
pubmed: 20166200
Invest Ophthalmol Vis Sci. 1991 May;32(6):1785-90
pubmed: 2032801
Biomacromolecules. 2010 May 10;11(5):1348-57
pubmed: 20355705
Prog Retin Eye Res. 2010 Nov;29(6):443-65
pubmed: 20398784
Prog Retin Eye Res. 2010 Nov;29(6):500-19
pubmed: 20488255
J Biomater Sci Polym Ed. 2011;22(1-3):59-75
pubmed: 20540835
Pharm Res. 1991 Jun;8(6):713-20
pubmed: 2062800
J Biomed Mater Res A. 2010 Dec 15;95(4):1233-43
pubmed: 20939049
Acta Biomater. 2011 Apr;7(4):1485-95
pubmed: 21168535
Biomaterials. 2011 May;32(14):3620-6
pubmed: 21320724
Angiogenesis. 2012 Jun;15(2):171-85
pubmed: 22302382
J Ophthalmic Vis Res. 2011 Oct;6(4):317-29
pubmed: 22454753
Am J Pathol. 2012 Aug;181(2):376-9
pubmed: 22749677
Eye (Lond). 2013 Jul;27(7):787-94
pubmed: 23722722
Pharm Res. 2014 Mar;31(3):742-53
pubmed: 24022682
Acta Biomater. 2014 Mar;10(3):1177-86
pubmed: 24321351
Ann Biomed Eng. 2015 Nov;43(11):2609-17
pubmed: 25835212
Int J Pharm. 2015 Jul 25;490(1-2):375-83
pubmed: 26027491
Eur J Pharm Biopharm. 2015 Nov;97(Pt B):338-49
pubmed: 26614556
Curr Eye Res. 2016 Sep;41(9):1216-22
pubmed: 26764892
Mol Pharm. 2016 Sep 6;13(9):2923-40
pubmed: 27286558
Expert Opin Drug Deliv. 2017 May;14(5):611-620
pubmed: 27551742
J Control Release. 2016 Dec 28;244(Pt A):1-13
pubmed: 27810558
J Ophthalmol. 2016;2016:5356371
pubmed: 27882245
Curr Eye Res. 2017 Sep;42(9):1293-1301
pubmed: 28557571
Nat Rev Mater. 2016 Dec;1(12):null
pubmed: 29657852
N Engl J Med. 1994 Dec 1;331(22):1480-7
pubmed: 7526212
J Biomater Sci Polym Ed. 1994;6(6):585-98
pubmed: 7873510
Invest Ophthalmol Vis Sci. 1997 Dec;38(13):2729-41
pubmed: 9418725